The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Mouse Models for Cancer Immunotherapy Research
Open accessAbstract
Immunotherapy has revolutionized cancer therapy, largely attributed to the success of immune-checkpoint blockade. However, there are subsets of patients across multiple cancers who have not shown robust responses to these agents. A major impediment to progress in the field is the availability of faithful mouse models that recapitulate the complexity of human malignancy and immune contexture within the tumor microenvironment. These models are urgently needed across all malignancies to interrogate and predict antitumor immune responses and therapeutic efficacy in clinical trials. Herein, we seek to review pros and cons of different cancer mouse models, and how they can be used as platforms to predict efficacy and resistance to cancer immunotherapies. Significance: Although immunotherapy has shown substantial benefit in the treatment of a variety of malignancies, a key hurdle toward the advancement of these therapies is the availability of immunocompetent preclinical mouse models that recapitulate human disease. Here, we review the evolution of preclinical mouse models and their utility as coclinical platforms for mechanistic interrogation of cancer immunotherapies. Cancer Discov; 8(11); 1358–65. ©2018 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 2×
“These models were used in the groundbreaking work by Schreiber and others to identify and characterize the process of immunoediting (4), using agents such as methylcholanthrene (MCA).”
BackgroundMethodHingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
A History of Cancer Chemotherapy
DeVita, V. T., & Chu, E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6611 · Cited by 1,970
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Prostate cancer in a transgenic mouse.
Greenberg, N. M., DeMayo, F., Finegold, M. J., Medina, D., Tilley, W. D., Aspinall, J. O., Cunha, G. R., Donjacour, A. A., Matusik, R. J., & Rosen, J. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3439 · Cited by 1,294
Heterogeneity in Cancer: Cancer Stem Cells versus Clonal Evolution
Shackleton, M., Quintana, E., Fearon, E. R., & Morrison, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.08.017 · Cited by 1,162
Ku, S. Y., Rosario, S., Wang, Y., Mu, P., Seshadri, M., Goodrich, Z. W., Goodrich, M. M., Labbé, D. P., Gomez, E. C., Wang, J., et al. (2017) · Science · doi:10.1126/science.aah4199 · Cited by 1,089
Targeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Liu, J., Blake, S. J., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., Young, A., O'Donnell, J. S., Allen, S., Smyth, M. J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0577 · Cited by 894
Sinn, E., Muller, W., Pattengale, P., Tepler, I., Wallace, R., & Leder, P. (1987) · Cell · doi:10.1016/0092-8674(87)90449-1 · Cited by 792
Developmental and tissue-specific regulation of mouse telomerase and telomere length.
Prowse, K. R., & Greider, C. W. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4818 · Cited by 690
Interrogating open issues in cancer precision medicine with patient-derived xenografts
Byrne, A. T., Alférez, D. G., Amant, F., Annibali, D., Arribas, J., Biankin, A. V., Bruna, A., Budinská, E., Caldas, C., Chang, D. K., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.140 · Cited by 657
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
Germano, G., Lamba, S., Rospo, G., Barault, L., Magrì, A., Maione, F., Russo, M., Crisafulli, G., Bartolini, A., Lerda, G., et al. (2017) · Nature · doi:10.1038/nature24673 · Cited by 627
Rapid Colorectal Adenoma Formation Initiated by Conditional Targeting of the Apc Gene
Shibata, H., Toyama, K., Shioya, H., Ito, M., Hirota, M., Hasegawa, S., Matsumoto, H., Takano, H., Akiyama, T., Toyoshima, K., et al. (1997) · Science · doi:10.1126/science.278.5335.120 · Cited by 605
Humanized Mouse Models of Clinical Disease
Walsh, N. C., Kenney, L. L., Jangalwe, S., Aryee, K.-E., Greiner, D. L., Brehm, M. A., & Shultz, L. D. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100332 · Cited by 562
Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model
Kaplan‐Lefko, P. J., Chen, T., Ittmann, M. M., Barrios, R. J., Ayala, G. E., Huss, W. J., Maddison, L. A., Foster, B. A., & Greenberg, N. M. (2003) · The Prostate · doi:10.1002/pros.10215 · Cited by 438
King, M. A., Covassin, L., Brehm, M. A., Racki, W., Pearson, T., Leif, J., Laning, J., Fodor, W., Foreman, O., Burzenski, L., et al. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2009.03933.x · Cited by 386
A Functional Role for Tumor Cell Heterogeneity in a Mouse Model of Small Cell Lung Cancer
Calbo, J., van Montfort, E., Proost, N., van Drunen, E., Beverloo, H. B., Meuwissen, R., & Berns, A. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.021 · Cited by 369
Humanized mice in studying efficacy and mechanisms of PD‐1‐targeted cancer immunotherapy
Wang, M., Yao, L., Cheng, M., Cai, D., Martinek, J., Pan, C., Shi, W., Ma, A., de Vere White, R. W., Airhart, S., et al. (2018) · The FASEB Journal · doi:10.1096/fj.201700740r · Cited by 339
Self-citationThe YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations
Meeth, K., Wang, J. X., Micevic, G., Damsky, W., & Bosenberg, M. W. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12498 · Cited by 318
Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution
Efremova, M., Rieder, D., Klepsch, V., Charoentong, P., Finotello, F., Hackl, H., Hermann-Kleiter, N., Löwer, M., Baier, G., Krogsdam, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02424-0 · Cited by 297
Eradication of established tumors in mice by a combination antibody-based therapy
Uno, T., Takeda, K., Kojima, Y., Yoshizawa, H., Akiba, H., Mittler, R. S., Gejyo, F., Okumura, K., Yagita, H., & Smyth, M. J. (2006) · Nature Medicine · doi:10.1038/nm1405 · Cited by 257
DuPage, M., Cheung, A. F., Mazumdar, C., Winslow, M. M., Bronson, R., Schmidt, L. M., Crowley, D., Chen, J., & Jacks, T. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.011 · Cited by 244
Wang, J., Perry, C. J., Meeth, K., Thakral, D., Damsky, W., Micevic, G., Kaech, S., Blenman, K., & Bosenberg, M. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12591 · Cited by 199
McFadden, D. G., Politi, K., Bhutkar, A., Chen, F. K., Song, X., Pirun, M., Santiago, P. M., Kim-Kiselak, C., Platt, J. T., Lee, E., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613601113 · Cited by 194 · cited 1×
“In addition, by overexpression or deletion of a select number of genes, the tumor mutational burden in genetically engineered models may not replicate that seen in the corresponding human disease (22, 23).”
BackgroundJespersen, H., Lindberg, M. F., Donia, M., Söderberg, E. M. V., Andersen, R., Keller, U., Ny, L., Svane, I. M., Nilsson, L. M., & Nilsson, J. A. (2017) · Nature Communications · doi:10.1038/s41467-017-00786-z · Cited by 160
Pajot, A., Michel, M., Fazilleau, N., Pancré, V., Auriault, C., Ojcius, D. M., Lemonnier, F. A., & Lone, Y. C. (2004) · European Journal of Immunology · doi:10.1002/eji.200425463 · Cited by 155
Madan, R. A., Gulley, J. L., Fojo, T., & Dahut, W. L. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0129 · Cited by 142
Jangalwe, S., Shultz, L. D., Mathew, A., & Brehm, M. A. (2016) · Immunity Inflammation and Disease · doi:10.1002/iid3.124 · Cited by 119
Immunotherapy for Prostate Cancer: Recent Advances, Lessons Learned, and Areas for Further Research
Gulley, J. L., & Drake, C. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2656 · Cited by 118
NSG Mice Provide a Better Spontaneous Model of Breast Cancer Metastasis than Athymic (Nude) Mice
Puchalapalli, M., Zeng, X., Mu, L., Anderson, A., Glickman, L. H., Zhang, M., Sayyad, M. R., Wangensteen, S. M., Clevenger, C. V., & Koblinski, J. E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163521 · Cited by 117
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines
Lohmueller, J. J., & Finn, O. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.008 · Cited by 101
Engineering humanized mice for improved hematopoietic reconstitution
Drake, A. C. B., Chen, Q., & Chen, J. (2012) · Cellular and Molecular Immunology · doi:10.1038/cmi.2012.6 · Cited by 99
Preclinical Models in Chimeric Antigen Receptor–Engineered T-Cell Therapy
Siegler, E. L., & Wang, P. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.243 · Cited by 97
Liu, J., Blake, S. J., Harjunpää, H., Fairfax, K. A., Yong, M. C. R., Allen, S. M., Kohrt, H. E. K., Takeda, K., Smyth, M. J., & Teng, M. W. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0194 · Cited by 95
Peripheral blood CD34+ cells efficiently engraft human cytokine knock-in mice
Saito, Y., Ellegast, J. M., Rafiei, A., Song, Y., Kull, D., Heikenwälder, M. F., Rongvaux, A., Halene, S., Flavell, R. A., & Manz, M. G. (2016) · Blood · doi:10.1182/blood-2015-10-676452 · Cited by 81
Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies
Liu, J., Blake, S. J., Smyth, M. J., & Teng, M. W. L. (2014) · Clinical & Translational Immunology · doi:10.1038/cti.2014.18 · Cited by 77
Targeting BRAF in an Inducible Murine Model of Melanoma
Hooijkaas, A. I., Gadiot, J., van der Valk, M., Mooi, W. J., & Blank, C. U. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.06.002 · Cited by 72
The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models
Yen, J. L., White, R. M., Wedge, D. C., Loo, P. V., de Ridder, J., Capper, A., Richardson, J., Jones, D., Raine, K. M., Watson, I. R., et al. (2013) · Genome biology · doi:10.1186/gb-2013-14-10-r113 · Cited by 48
Hasgur, S., Aryee, K., Shultz, L. D., Greiner, D. L., & Brehm, M. A. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3661-8_4 · Cited by 47
Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1
Wright, M. H., Robles, A. I., Herschkowitz, J. I., Hollingshead, M. G., Anver, M. R., Perou, C. M., & Varticovski, L. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-29 · Cited by 45
Telomere Dysfuction Promotes Metastasis in a TERC Null Mouse Model of Head and Neck Cancer
Bojović, B., & Crowe, D. L. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0345 · Cited by 21
Cited by
Crosby, D., Bhatia, S., Brindle, K. M., Coussens, L. M., Dive, C., Emberton, M., Esener, S., Fitzgerald, R. C., Gambhir, S. S., Kuhn, P., et al. (2022) · Science · doi:10.1126/science.aay9040 · Cited by 1,379
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Martinez, A. B., Chan, T. A., Coukos, G., Demaria, S., Deutsch, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337 · Cited by 1,119
Embracing cancer complexity: Hallmarks of systemic disease
Swanton, C., Bernard, E., Abbosh, C., André, F., Auwerx, J., Balmain, A., Bar-Sagi, D., Bernards, R., Bullman, S., DeGregori, J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.009 · Cited by 540
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
Cossarizza, A., Chang, H., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreata, F., Annunziato, F., Arranz, E., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202170126 · Cited by 531
Organoid and Spheroid Tumor Models: Techniques and Applications
Gunti, S., Hoke, A. T. K., Vu, K. P., & London, N. R. (2021) · Cancers · doi:10.3390/cancers13040874 · Cited by 479
Metadata
- Authors
- Olson, B., Li, Y., Lin, Y., Liu, E. T., & Patnaik, A.
- Venue
- Cancer Discovery
- Published
- 2018-11-01
- Volume
- 8
- Issue
- 11
- Pages
- 1358-1365
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2897100571
- Cited by
- 435
- References
- 46
- FWCI
- 11.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.